STAA — STAAR Surgical Company stock price, charts and financials

QT53STAAR Surgical Company

STAAR Surgical Company (NASDAQ: STAA) is a Healthcare company in the Medical - Instruments & Supplies industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
25.26
+1.05+4.34%
STAAQT53STAAR Surgical Company·NASDAQ
25.26+4.34%
Earnings
Up 4.3% — Earnings due 2026-08-12 — pre-report positioning.
Medium confidence
TA
Loading chart...
Screen all →
Snapshot
Index-P/E-EPS (ttm)-0.42Insider Own35.13%Shs Outstand49.79MPerf Week-0.62%
Market Cap1.21BForward P/E25.28EPS next Y0.96Insider Trans3.83%Shs Float49.39MPerf Month-13.44%
Enterprise Value1.11BPEG-EPS next Q-Inst Own-Short Float10.31%Perf Quarter-11.25%
Income-20.97MP/S4.15EPS this Y270.01%Inst Trans-Short Ratio6.26Perf Half Y41.83%
Sales290.38MP/B3.43EPS next Y34.13%ROA-4.66%Short Interest5.09MPerf YTD4.85%
Book/sh-P/C-EPS next 5Y27.38%ROE-6.07%52W High37.43 -32.51%Perf Year-10.00%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-1.26%52W Low16.27 55.29%Perf 3Y-53.71%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-5.59% 7.95%Gross Margin76.43%Volatility5.47% 5.47%Perf 5Y-81.07%
Dividend TTM-EV/Sales3.83EPS Y/Y TTM-2.44%Oper. Margin-1.72%ATR (14)1.39Perf 10Y258.14%
Dividend Ex-Date-Quick Ratio4.31Sales Y/Y TTM-7.32%Profit Margin-7.24%RSI (14)43.83Recom2.80
Dividend Gr. 3/5Y-Current Ratio5.12EPS Q/Q173.08%SMA20-2.43%Beta1.21Target Price32.60
Payout0.00%Debt/Eq0.11Sales Q/Q118.60%SMA50-11.11%Rel Volume0.88Prev Close24.21
Employees957LT Debt/Eq0.09EarningsAug 12SMA200-0.33%Avg Volume914.78KPrice25.26
IPO DateFeb 24, 1992Option/ShortYes / YesEPS/Sales Surpr.600.84% 18.81%Net Debt/EBITDA23.03Volume808,210Change4.34%
Analyst Ratings
DateActionAnalystRatingTarget
May-14-26ReiteratedStifel Nicolaus$18$31
May-14-26ReiteratedCanaccord GenuityBuy$27$32
May-14-26ReiteratedMizuhoNeutral$27
May-14-26UpgradeWedbushNeutralOutperform$26$40
May-14-26ReiteratedPiper SandlerNeutral$33
Apr-09-26UpgradeCanaccord GenuityHoldBuy$22$27
Mar-04-26ReiteratedStifel Nicolaus$19$18
Feb-09-26ReiteratedStifel Nicolaus$28$19
Feb-03-26InitiatedWedbushNeutral$26
Jan-16-26ResumedMorgan StanleyUnderweight$13
Latest News
Aug-05-26
Aug-04-26
Jul-22-26
Jul-17-26
Jul-17-2605:31PM
Jul-16-26
Company

STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
FY 2025
1/2/2026
FY 2024
12/27/2024
FY 2023
12/29/2023
FY 2022
12/30/2022
FY 2021
12/31/2021
FY 2020
1/1/2021
FY 2019
1/3/2020
FY 2018
12/28/2018
Total Revenue291239314
Cost of Goods Sold Incl. D&A695774
Gross Profit223182240
Selling, General and Administrative Excl. Other176188198
Research and Development384054
Other Operating Expense
1300
Operating Income-6-46-13
Interest Expense
000
Unusual Expense
Non-Operating Income (Expense)-15-364
Net Income Before Taxes-20-82-9
Income Taxes2-211
Consolidated Net Income-21-80-20
Net Income From Continuing Operations-21-80-20
Net Income-21-80-20
EPS (Recurring)-0.42-1.62-0.41
EPS (Basic, Before Extraordinaries)-0.42-1.62-0.41
EPS (Diluted)-0.42-1.62-0.41
EBITDA-5-74-2
Other After Tax Adjustments
Stock Option Compensation Expense
Price To Earnings Ratio
Price To Sales Ratio4.344.943.78
Gross Margin76.6376.1576.43
Operating Margin-2.06-19.25-4.14
Net Margin-7.22-33.47-6.37
Shares Outstanding505049
Market Capitalization1,2631,1801,186
Operating Lease Expense
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$35.93$30.32$24.72$19.12$13.51 Close Price0.00M10.27M20.53M30.80M41.06MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Foust WarrenPresident and CEOJul 31 '26Option Exercise0.0020,787097,132Aug 04
ANDREWS DEBORAH JChief Financial Officer & EVPJul 31 '26Option Exercise0.0020,787046,915Aug 04
ANDREWS DEBORAH JChief Financial Officer & EVPJun 25 '26Option Exercise0.0013,955032,608Aug 04
SILVERMAN LOUDirectorJun 18 '26Option Exercise0.0010,683011,158Jun 22
Jiang WeiDirectorJun 18 '26Option Exercise0.0010,683077,127Jun 22
Butcher Arthur CDirectorJun 18 '26Option Exercise0.005,34109,549Jun 22
Michna MagdaChief Development OfficerMay 15 '26Option Exercise0.0019,795019,795May 19
ANDREWS DEBORAH JInterim Co-CEO and CFOMay 15 '26Option Exercise0.0015,699015,699May 19
Foust WarrenInterim Co-CEO and Pres. & COOMay 15 '26Option Exercise0.0032,990032,990May 19
Michna MagdaChief Development OfficerMar 14 '26Option Exercise0.0017,595036,001Mar 16
Foust WarrenInterim Co-CEO and Pres. & COOMar 14 '26Option Exercise0.0029,325063,588Mar 16
Foust WarrenInterim Co-CEO and Pres. & COOMar 12 '26Option Exercise0.008,175034,263Mar 16
Michna MagdaChief Development OfficerMar 12 '26Option Exercise0.006,178020,622Mar 16
BROADWOOD PARTNERS, L.P.director, 10 percent owner:Mar 13 '26Buy18.61316,0175,882,65616,123,842Mar 13
BROADWOOD PARTNERS, L.P.director, 10 percent owner:Mar 12 '26Buy18.12299,4325,424,33015,807,825Mar 13
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.